Shane Schaffer is the co-founder, Chairman, and chief executive officer of Cingulate Therapeutics, a biopharmaceutical company based in Kansas City, Kansas, that is in the Phase 3 clinical stage. The company focuses on developing next-generation pharmaceutical products, with a particular emphasis on treating Attention Deficit/Hyperactivity Disorders (ADHD) and other conditions such as anxiety disorders and insomnia.
With over 25 years of experience in the pharmaceutical industry, he has become an expert in drug development and commercialization. A proactive approach to various aspects of business operations, including product launches, brand planning, and joint venture brand management, marks his leadership. His academic credentials include a doctoral degree in Pharmacy from the University of Kansas, completed in 1999, and a postdoctoral fellowship at Rutgers University’s College of Pharmacy, where he worked with Pfizer Worldwide Marketing and Morris Plains.
While at Pfizer Worldwide Marketing in New York, he took on the role of Marketing Manager, spearheading pre-launch strategies and initiating the Global Communications Intranet to facilitate communication between medical and marketing teams. At Morris Plains in New Jersey, he managed the initiation of Phase IV Medical Research for all marketed brands and led advanced sales and management training programs.
He then joined Novartis Pharmaceuticals Corporation as a Product Manager for its ADHD medication segments, Ritalin® LA and Focalin™, achieving significant market penetration and product awareness shortly after launch. His leadership in these roles earned him multiple awards for business excellence.
Following his time at Novartis, he contributed to Sanofi-Aventis and its predecessors, where he was instrumental in the promotional campaigns and market strategies for products like Avapro and Avalide, which were part of a joint venture with Bristol-Myers Squibb. He also managed the promotion and strategy for Hyalgan, Eligard, and Arixtra, securing a high budget attainment and strengthening professional relationships within the industry.
Before founding his consulting firm, Sabre Scientific Solutions, LLC, he worked as a consultant with M|C Communications LLC in Boston, where he developed business opportunities with major pharmaceutical companies.
In 2013, he established Cingulate Therapeutics LLC, driven by his passion for improving ADHD and anxiety disorder treatments through innovative drug-delivery technologies. His company aims to reduce patients' dependency on medications by enhancing drug delivery systems.
Cingulate recently partnered with Indegene to market its oral ADHD medication, CTx-1301, now in Phase 3 trials. The company plans to submit a new drug application to the FDA by mid-2025.
Beyond his corporate responsibilities, Shane Schaffer is dedicated to philanthropic efforts, particularly with the Folds of Honor Charity, which provides scholarships and educational support to children of fallen or disabled military personnel. His commitment to both his professional and philanthropic endeavors highlights his comprehensive approach to leadership and community engagement.
